TP53 and B-cell chronic lymphocytic leukemia: While the development of these effective CIT regimens marked a significant advance in the management of CLL, responses in patients whose disease harboured abnormalities in TP53 were less frequent and typically short-lived[7], and the toxicity of the most efficacious regimens precluded their use in a high proportion of patients, given the advanced median age and frequent comorbidity at CLL diagnosis[8].